Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr där Industrifonden, Östersjöstiftelsen och Sciety-nätverket deltog. Det nya kapitalet ska användas för en klinisk fas 2-studie och bolaget siktar på ett förvärv från en större aktör efter att studien är genomförd.
Athera Biotechnologies AB Olof Palmes gata 29, 4th floor 111 22 Stockholm, Sweden. James Hall, CEO E-mail: j.hall@athera.se. Reg. No. 556620-6859
Phone Number +46761938190 Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). Description Operator of biopharmaceutical company intended to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease (CVD). At Athira, We Value Connections Athira is derived from the word Athir, the energy that reaches everyone. It captures our mission to develop therapies that can reach and positively impact everyone.
- Blackrock technology opportunities fund
- Produktionsplanering engelska
- Varhennettu vanhuuseläke verotus
- Hur manga timmar jobbar man per ar
- Nu vet jag vad kärlek är
- Dbx dirt bike
- Miljöpartiet partiledare genom tiderna
- Garnisonen hassleholm
- Vikingaskolan lund parkering
Athera Biotechnologies okt 2006 –nu 14 år 6 månader. Preclinical development of drug projects within Cardiovascular Disease drug development consultant self employed consultant jan 2003 –nu 18 år 3 månader. drug project development A+ Science 2019-05-14 Athera Biotechnologies. Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease. The Company initiated its current program in 2005, Athera Biotechnologies.
Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients. We are now pursuing clinical development with our anti-inflammatory antibody.
Taggar: Pågående uppdrag: Styrelseordförande i Athera Biotechnologies AB. Styrelseledamot i Olsson Solutions AB, IRLAB Sweden, Gesynta Pharma AB, European Society of Cardiology och Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt- och lungsjukdomar. Aktieinnehav: 2 000 A-aktier. 2019-05-21 About Athera Biotechnologies . Athera develops anti-inflammatory medicine to treat vascular disease and conditions with major medical requirements, with a focus on the pharmaceutical candidate ATH3G10.
May 17, 2017 A recent press release from Athera Biotechnologies describes how Olink panels were used to measure 251 proteins in a longitudinal study of
Athera Biotechnologies AB, http://www.athera.se. Atnahs Pharma Nordics A/S. Atossa Therapeutics, Inc. in life science. We invest in biotechnology, health tech, ICT in healthcare, pharmaceuticals, and medical technology. Athera Biotechnologies.
Athera Biotechnologies announces that the last patient has been dosed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure. The study completed recruitment by including 82 patients with STEMI and aims for results to be presented in 2020.
Sernik bez sera
Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease.
Following completion of three Phase 1 studies, the company has now raised the capital for completion of a clinical Proof-of-Concept Phase 2 study, with the aim to close an agreement with a larger pharmaceutical company once the study is complete. Senior Bussines Advisor, Athera Biotechnologies AB - Chairwoman of AdBIOPRO Centre Board Assoc.
Lista photography aiken sc
konteradmiral von puttkamer
göteborgs universitet specialistsjuksköterska
violence against men
europcar bilklasser
lundbergforetagen aktier
Hitta information om Athera Biotechnologies AB. Adress: Sankt Eriksgatan 117, Postnummer: 113 43. Telefon: 08-728 60 ..
Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock Athera Biotechnologies AB is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (CVD). The company has a proprietary clinical development stage program with the lead candidate, ATH3G10. Proff.se ger dig företagsinformation om Athera Biotechnologies AB, 556620-6859.
Datorteknik umeå
barnskadespelare usa
Mynewsdesk: Athera uppnår inklusionsmålet för hjärtsviktstudie. Stockholm April 2, 2020 Athera Biotechnologies AB, ett svensk. 4.4.2021. Börse frankfurt
Athera's flagship product is an antibody that Biotechnology. Instigating 3-D Sequencing.
Karolinska Development said today that it is divesting its entire shareholding in the drug development… Athera BiotechnologiesBiotechnologyCardio-vascular
Preclinical development of drug projects within Cardiovascular Disease drug development consultant self employed consultant jan 2003 –nu 18 år 3 månader. drug project development A+ Science 2019-05-14 Athera Biotechnologies.
1. Aktiekapital. Företagsinformation.